**Lymphocytic**
- R/R CD19+ precursor B-lymphoblastic leukemia
- CD3+ acute lymphoma, or poor-risk chronic subtypes of adult T-cell lymphoma/leukemia

**Myelogenous**
- R/R AML, myelodysplastic syndrome, or chronic myelomonocytic leukemia
- AML with wild-type p53 (R/R or front line)
- AML in complete remission
- AML associated with antecedent myeloproliferative disorder

**Mutated AML**
- AML (front line therapy)

**Myelodysplastic syndrome**
- MDS or oligoblastic AML

**Hematologic malignancy**
- Hematologic malignancy, not otherwise stated

**Leukemia**
- **NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: November 20, 2019

- **10300:** MPD-ERASER 1: Randomized Phase 2 Study of the Anti-PD-L1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia
- **10335:** A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
- **10030:** MPD-ERASER 1: Randomized Phase 2 Study of the Anti-PD-L1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia
- **10026:** A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
- **10247:** A Randomized Phase II Trial of MLN4924 (Pevonedistat) with Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia
- **10246:** A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- **10237:** A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents
- **10273:** A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia
- **9706:** Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
- **10200:** A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia
- **10317:** A Pilot Study of Nivolumab in Combination with Decitabine and Venetoclax in TP53-Mutated Acute Myeloid Leukemia
- **10334:** Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2: A Randomized Phase 2 Study of Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine as First Line Therapy in Older Patients with Acute Myeloid Leukemia Who Are Ineligible or Who Refuse Intensive Chemotherapy
- **10909:** A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
- **10147:** A Phase II Randomized Study of Topotecan/Carboplatin with or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)
- **1075:** A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine in Acute Myeloid Leukemia
- **10367:** A Phase 1b Study with Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML)
- **9706:** Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
- **10147:** A Phase II Randomized Study of Topotecan/Carboplatin with or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)
- **10200:** A Phase Ib/Ii Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia
- **10317:** A Pilot Study of Nivolumab in Combination with Decitabine and Venetoclax in TP53-Mutated Acute Myeloid Leukemia
- **10212:** A Phase 1b/2 Study of Pinometostat in Combination with Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with MLL Rearrangement
- **10300:** MPD-ERASER 1: Randomized Phase 2 Study of the Anti-PD-L1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia
- **10334:** Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2: A Randomized Phase 2 Study of Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine as First Line Therapy in Older Patients with Acute Myeloid Leukemia Who Are Ineligible or Who Refuse Intensive Chemotherapy
- **10009:** A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
- **10014:** A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
- **10075:** A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine in Acute Myeloid Leukemia